1 Retrospective case-control studies on cancer risk are susceptible to recall bias
However, some studies are exploring their potential benefits in this population, but they are not currently recommended
The GLP-1 market growth is driven by advancements in drug formulations, particularly the development of oral and long-acting therapies
The appetite-suppressing effects might reduce binge eating but could also reinforce the food restriction that typically precedes binges and worsen the cycle overall ( Schaefer et al., Psychiatric Clinics of North America, 2026 )
GLP-1 weight loss injections, such as Semaglutide and Tirzepatide, mimic this hormones effects, helping to control hunger and stabilize blood sugar levels
Hamed K, Amirhossein D, Fatemeh D, Seyed Mohamad Ali M, Zahra Razaghi B, Michael A, et al